Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + fluorouracil + goserelin + tamoxifen

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Subcutaneous, Oral

Overview

A combination therapy regimen consisting of three chemotherapeutic agents (cyclophosphamide, doxorubicin, and fluorouracil) plus two endocrine therapy agents (goserelin and tamoxifen). The chemotherapy component is commonly known as FAC or CAF. This combination is used for the treatment of hormone receptor-positive breast cancer, particularly in premenopausal women. The addition of goserelin provides ovarian function suppression, while tamoxifen acts as an estrogen receptor antagonist in breast tissue.

Targets

TS (Thymidylate synthase)GnRHR (Gonadotropin-releasing hormone receptor)ESR1 (ERα)TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + fluorouracil + goserelin + tamoxifen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + fluorouracil + goserelin + tamoxifen.

Explore the full profile